Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Regular update of the Norwegian Laboratory Code System released

On May 23, 2024, the Norwegian Directorate of Health released an updated version of the Norwegian Laboratory Code (NLK) system (Norsk laboratoriekodeverk 7280.72) and associated tariffs (Laboratoriekodeverk som gir rett til refusjon) for state and private laboratories to be implemented no later than July 1, 2024. NLK system is used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) for laboratory tests performed in outpatient settings.

Twenty-two new codes were added in medical biochemistry, medical microbiology, and clinical pharmacology fields. Some examples of the newly added codes are:

  • NPU62637 DNA MCM6 gene (NG_008958.1:g.30267T>G) Lactose intolerance;
  • NOR35331 Cult-Staphylococcus (mecA) (culture);
  • NPU58099 Us-Neisseria gonorrhea DNA (Chinolone-resistant) (unspecified sample);
  • NPU62639 Secr(Cervix uteri)-Human papillomavirus type 56, 59, 66 DNA (cervical secretions);
  • NPU62793 F-Enterococcus (Linezolid-resistant) culture (feces).

Furthermore, 49 codes were amended.

See the full details in Norwegian here (codes) and here (tariffs).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.